X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Lupin Ltd with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs TEVA PHARMA (Israel) - Comparison Results

LUPIN    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 LUPIN   TEVA PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-18
TEVA PHARMA
Dec-13
LUPIN/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4652,890-   
Low Rs7272,511-   
Sales per share (Unadj.) Rs349.61,658.7-  
Earnings per share (Unadj.) Rs5.6103.6-  
Cash flow per share (Unadj.) Rs29.6237.7-  
Dividends per share (Unadj.) Rs5.0090.70-  
Dividend yield (eoy) %0.53.4 13.6%  
Book value per share (Unadj.) Rs300.31,842.5-  
Shares outstanding (eoy) m452.08848.00-   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.11.6 192.6%   
Avg P/E ratio x197.226.1 756.7%  
P/CF ratio (eoy) x37.111.4 326.2%  
Price / Book Value ratio x3.61.5 249.0%  
Dividend payout %90.087.5 102.8%   
Avg Mkt Cap Rs m495,5022,289,905 21.6%   
No. of employees `00017.044.9 37.9%   
Total wages/salary Rs m28,6470-   
Avg. sales/employee Rs Th9,273.631,294.7 29.6%   
Avg. wages/employee Rs Th1,681.00-   
Avg. net profit/employee Rs Th147.41,955.0 7.5%   
INCOME DATA
Net Sales Rs m158,0421,406,541 11.2%  
Other income Rs m1,5040-   
Total revenues Rs m159,5451,406,541 11.3%   
Gross profit Rs m31,475385,182 8.2%  
Depreciation Rs m10,859113,692 9.6%   
Interest Rs m2,04427,627 7.4%   
Profit before tax Rs m20,076243,863 8.2%   
Minority Interest Rs m-711,108 -6.4%   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,644-160,083 9.1%   
Tax Rs m2,885-2,977 -96.9%   
Profit after tax Rs m2,51387,866 2.9%  
Gross profit margin %19.927.4 72.7%  
Effective tax rate %14.4-1.2 -1,176.8%   
Net profit margin %1.66.2 25.4%  
BALANCE SHEET DATA
Current assets Rs m122,095949,973 12.9%   
Current liabilities Rs m50,956828,457 6.2%   
Net working cap to sales %45.08.6 521.0%  
Current ratio x2.41.1 209.0%  
Inventory Days Days8591 93.2%  
Debtors Days Days12096 125.0%  
Net fixed assets Rs m129,876459,407 28.3%   
Share capital Rs m9043,462 26.1%   
"Free" reserves Rs m134,8660-   
Net worth Rs m135,7711,562,401 8.7%   
Long term debt Rs m64,245719,196 8.9%   
Total assets Rs m263,0543,214,398 8.2%  
Interest coverage x10.89.8 110.2%   
Debt to equity ratio x0.50.5 102.8%  
Sales to assets ratio x0.60.4 137.3%   
Return on assets %1.73.6 48.2%  
Return on equity %1.95.6 32.9%  
Return on capital %3.74.9 75.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m33,8070-   
CASH FLOW
From Operations Rs m17,512224,130 7.8%  
From Investments Rs m-14,073-79,418 17.7%  
From Financial Activity Rs m-14,921-268,859 5.5%  
Net Cashflow Rs m-11,482-124,147 9.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 69.24 Rs / USD

Compare LUPIN With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare LUPIN With: WYETH LTD  SHASUN PHARMA  NATCO PHARMA  TORRENT PHARMA  ALEMBIC LTD  



Today's Market

Rising Crude Oil Prices, DHFL's CP Default, and Top Cues in Focus Today(Pre-Open)

On Wednesday, share markets in India traded on a positive note most of the day and ended marginally higher. The BSE Sensex closed higher by 157 points to end the day at 39,592.

Related Views On News

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

This Little-Known Opportunity Promises Both Health and Wealth for Your Grandchildren(Profit Hunter)

Jun 20, 2019

The next big opportunity that has the potential to make you both rich and healthy.

My Upcoming Stock Recommendation, Backed by Aberdeen Standard Investments, Scores 9.1/10(The 5 Minute Wrapup)

Jun 19, 2019

This month's Smart Money Secrets recommendation is from global super investor - Aberdeen Standard Investments.

One Stock that Will Gain from the Electric Vehicle Disruption(The 5 Minute Wrapup)

Jun 25, 2019

Even if the share of the unorganized segment does not fall sharply, one player in the duopolistic battery sector has a lot to gain.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Jun 26, 2019 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS